These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37308105)

  • 21. Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.
    Abdelgani S; Puckett C; Adams J; Triplitt C; DeFronzo RA; Abdul-Ghani M
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3497-3504. PubMed ID: 34343296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of C-peptide in children: when is it useful?
    Besser RE
    Pediatr Endocrinol Rev; 2013 Jul; 10(4):494-502. PubMed ID: 23957200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of idiopathic type 1 diabetes with subsequent recovery of endogenous insulin secretion despite initial diagnosis of fulminant type 1 diabetes.
    Kaneko K; Satake C; Yamamoto J; Takahashi H; Sawada S; Imai J; Yamada T; Katagiri H
    Endocr J; 2017 Mar; 64(3):369-374. PubMed ID: 28070056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of insulin administration during the mixed meal tolerance test.
    Besser RE; Jones AG; McDonald TJ; Shields BM; Knight BA; Hattersley AT
    Diabet Med; 2012 Oct; 29(10):1279-84. PubMed ID: 22435709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical value of C-peptide determination].
    Meier C; Ladewig A; Keller U; Berger W
    Praxis (Bern 1994); 1997 Aug; 86(34):1289-95. PubMed ID: 9381016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetes Care; 2018 Dec; 41(12):2669-2701. PubMed ID: 30291106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
    Diabetologia; 2020 Feb; 63(2):221-228. PubMed ID: 31853556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
    Marx N; Davies MJ; Grant PJ; Mathieu C; Petrie JR; Cosentino F; Buse JB
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):46-52. PubMed ID: 33159841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
    Spirk D; Lareida J; Scheidegger K; Diem P
    Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
    Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
    Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
    Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
    Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
    Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critique of the 2012 ADA/EASD position statement.
    Rodbard HW; Jellinger PS
    Diabetologia; 2012 Oct; 55(10):2850-2852. PubMed ID: 22801905
    [No Abstract]   [Full Text] [Related]  

  • 35. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline.
    Peters AL; Ahmann AJ; Battelino T; Evert A; Hirsch IB; Murad MH; Winter WE; Wolpert H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):3922-3937. PubMed ID: 27588440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of type 2 diabetes: new or previous agents, how to choose?].
    Halimi S
    Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE.
    Cornell S
    J Am Pharm Assoc (2003); 2017; 57(2):261-265. PubMed ID: 28065547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.
    Maddaloni E; Bolli GB; Frier BM; Little RR; Leslie RD; Pozzilli P; Buzzetti R
    Diabetes Obes Metab; 2022 Oct; 24(10):1912-1926. PubMed ID: 35676794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-centred care in type 2 diabetes mellitus - Key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report.
    Fritzen K; Stautner C; Schnell O
    Diabetes Res Clin Pract; 2019 Dec; 158():107897. PubMed ID: 31672502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
    Abdul-Ghani M; DeFronzo RA
    Expert Opin Pharmacother; 2021 Nov; 22(16):2113-2125. PubMed ID: 34435523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.